Loss-of-function mutations in PCSK9 were determined to reduce LDL-C levels by 15-28% and the risk of coronary heart disease by 47-88%, so monoclonal antibodies that act as PCSK9 inhibitors sequester PCSK9 and thereby prevent LDL receptor destruction, leading to an increase in LDL receptor density on hepatocytes and lowering of LDL-C levels [6]. The gene discussed is LDLR; the disease is coronary artery disorder.